Home
Storia in 1 fonti
LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00.Claim 55% Off Ti...
Raccontata da
markets.businessinsider.com
Timeline cronologica
- ·
LifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)
LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Inhibrx Biosciences Inc today and set a price target of $230.00.Claim 55% Off...
- ·
LifeSci Capital Remains a Buy on Ibio (IBIO)
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00.Claim 55% Off Tip...
- ·
LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $24...
- ·
LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00.Claim 55% Off Ti...
- ·
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Neurogene today and set a price target of $60.00.Claim 55% Off TipRanksUnlock...